214450.KQ 21

214450.KQ PharmaResearch Co., Ltd.

Healthcare · Biotechnology

4 · Schwach Momentum 0.0 · Schwach Sicher 6J.-Serie

247500.00

-0.60%

Über das Unternehmen

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

1.49% erwartet
—
1.49% 3700.00 KRW
3700.00
2.6T
—
—
330952.50

52-Wochen-Spanne

247500
Tief 0.00 Hoch 561000
Rendite Wachstum Momentum Sicherheit Wert Gesundheit

Dividenden-Tiefenanalyse

PharmaResearch Co., Ltd. (214450.KQ) is an equity. The company currently offers a dividend yield of 1.49%. Information regarding its dividend safety status, momentum score, and value score is not provided in the data. The 5-year average, low, and high yield band data are also missing, preventing a comparison of the current yield to its historical range.

Dividendenhistorie

The dividend history for PharmaResearch Co., Ltd. (214450.KQ) shows a current annual dividend of 3,700 KRW. The data does not provide a streak of consecutive dividend increases. Similarly, the 3-year and 5-year dividend Compound Annual Growth Rates (CAGR) are missing from the provided information. The year-by-year dividend history is also not available in the dataset. Therefore, a detailed analysis of past dividend growth and consistency cannot be performed based on the provided figures.

Dividendensicherheit

Assessing the safety of PharmaResearch Co., Ltd.'s dividend of 3,700 KRW is limited by the available data. The payout ratio, which indicates what percentage of earnings are distributed as dividends, is missing.

Quantic · Kostenlos

Lies den Rest zur Dividendensicherheit

Dazu die wichtigsten Risiken und worauf als Nächstes zu achten ist. Kostenlos, ohne Karte.

KI-generiert aus den Dividendendaten von Quantic · Aktualisiert am 11 Nov 2026 · Nur zur Information – keine Finanzberatung.

Auf Englisch angezeigt — eine Übersetzung folgt in Kürze.

Kursverlauf

680000 368100 56200 2021 2022 2023 2024 2025 2026 2020-11 · 57200 2020-12 · 61600 2021-01 · 56200 2021-02 · 66300 2021-03 · 70000 2021-04 · 84200 2021-05 · 90000 2021-06 · 88800 2021-07 · 96900 2021-08 · 84700 2021-09 · 92000 2021-10 · 77200 2021-11 · 82000 2021-12 · 75400 2022-01 · 87100 2022-02 · 91800 2022-03 · 93000 2022-04 · 82700 2022-05 · 67400 2022-06 · 72600 2022-07 · 67500 2022-08 · 56600 2022-09 · 61500 2022-10 · 67000 2022-11 · 69900 2022-12 · 77200 2023-01 · 74400 2023-02 · 70200 2023-03 · 101000 2023-04 · 114700 2023-05 · 143700 2023-06 · 133200 2023-07 · 144900 2023-08 · 126500 2023-09 · 116400 2023-10 · 108400 2023-11 · 109500 2023-12 · 105300 2024-01 · 93900 2024-02 · 100900 2024-03 · 127600 2024-04 · 146100 2024-05 · 148800 2024-06 · 134100 2024-07 · 174500 2024-08 · 192700 2024-09 · 225500 2024-10 · 198000 2024-11 · 262500 2024-12 · 241500 2025-01 · 291000 2025-02 · 332000 2025-03 · 376500 2025-04 · 451000 2025-05 · 493500 2025-06 · 557000 2025-07 · 680000 2025-08 · 601000 2025-09 · 541000 2025-10 · 470000 2025-11 · 403000 2025-12 · 473500 2026-01 · 349500 2026-02 · 299000 2026-03 · 313500 2026-04 · 295000 2026-05 · 363000 2026-06 · 338500 2026-07 · 426000 2026-08 · 310500 2026-09 · 212000 2026-10 · 249000 2026-11 · 247500
Kurs

Dividendenprofil

Frequenz
Jährlich
Wachstum (TTM)
+236.4%
CAGR 3J
+77.6%
+49.2%
6 Jahre

(5 Jahre)

Jetzt 1.5%
0.7% Ø 0.8% 0.9%

Jan
Feb
Mär
Apr
Mai
Jun
Jul
Aug
Sep
Okt
Nov
Dez

Das Geld kommt meist später an, manchmal einen Monat oder mehr danach.

Dividendenhistorie

CAGR 3J +77.6% CAGR 5J +49.2% 6J.-Serie
15 16 17 18 19 20 21 22 23 24 25

Dividende je Aktie nach Jahr

Quantic · Kostenlos

Bewertung & Strategie freischalten

Zwei DDM-Fair-Values, Sicherheitsmarge, Bewertungsrang im Sektor, Dividendenrendite-Theorie, Verdopplungszeit und maximaler Drawdown.

Verschuldung & Hebel

27.9%
7.78
6.61
Schulden vs Barmittel
Schulden Barmittel
Gesamtverschuldung
220.3B KRW
Liquide Mittel gesamt
595.6B KRW
252.6B KRW

Zuletzt gemeldete Bilanzkennzahlen.

Erscheint in diesen Listen

214450.KQ erfüllt die Kriterien dieser Dividenden-Rankings.

Nur zur Information – keine Finanzberatung.

Quantic · Kostenlos

Verfolge 214450.KQ und dein ganzes Portfolio

Echte Rendite, Dividendensicherheit, Nettoeinkommen nach Steuern und dein Weg zur Freiheit — kostenlos, ohne Broker-Verbindung.

€0

Brauchst du mehr? Pro bringt mehr Portfolios, Optionseinkommen-Tracking und mehr KI. Pro ansehen →